AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10711075
Drug: Control (regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (regular insulin)
Trial: 7574775
Drug: Intraperitoneal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal infusion of methotrexate (MTX) and 5-fluorouracil (5-FU)
Trial: 7574775
Drug: Intraperitoneal infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraperitoneal infusion of methotrexate (MTX)
Trial: 7574775
Drug: Intraarterial (IA)
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraarterial (IA) administration of MTX
Trial: 7574775
Drug: Intravenous (IV)
RxNorm normalized name: intravenous (IV) infusion pump
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (IV) administration of MTX
Trial: 21751861
Drug: High-volume (170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-volume (170 mL) ropivacaine (0.2%) with epinephrine (1:100,000)
Trial: 19504141
Drug: Clopidogrel hydrogensulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogensulfate (CHS, 300 mg loading, followed by 75 mg/day)
Trial: 19504141
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (CB, 300 mg loading, followed by 75 mg/day)
Trial: 19504141
Drug: Clopidogrel hydrogensulfate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel hydrogensulfate (CHS, 5 micromol/L ADP)
Trial: 19504141
Drug: Clopidogrel besylate
RxNorm normalized name: Clopidogrel besylate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel besylate (CB, 5 micromol/L ADP)
Trial: 15504308
Drug: Omeprazole (OME)
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole (OME) 20 mg
Trial: 11096461
Drug: vit C‐1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vit C‐1500 (1500 mg/day)
Trial: 11096461
Drug: vit C‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vit C‐500 (500 mg/day)
Trial: 9151231
Drug: Boron neutron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Boron neutron capture therapy (BNCT) using p-boronophenylalanine (BPA) at a dose of 250 mg BPA/kg body weight during a 2-hour infusion.
Trial: 3533568
Drug: nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nifedipine (10 mg X 5)
Trial: 15816573
Drug: Saline 2
RxNorm normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline 2 mL (Group S)
Trial: 10619585
Drug: Calcium supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplementation (1 g elemental calcium, twice daily for 16 weeks)
Trial: 10619585
Drug: Placebo (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (twice daily for 16 weeks)
Trial: 1921241
Drug: Intravenous zinc
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous zinc supplementation for 8 weeks
Trial: 26050650
Drug: Vincristine-steroid pulses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vincristine-steroid pulses during maintenance
Trial: 21610711
Drug: Oral temozolomide
RxNorm normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Oral temozolomide (200 mg m(‐2) per day; days 1‐5)
Trial: 21610711
Drug: Intravenous dacarbazine
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous dacarbazine (800 mg m(‐2); day 1)
Trial: 1837121
Drug: Horse ALG
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse ALG 15 mg/kg just before transplant surgery; ALG 12 mg/kg on the first day after transplant followed by 4 doses of 10 mg/kg on alternate days; CyA p.o 8 mg/kg/d; prednisone 0.25 mg/kg/d
Trial: 1837121
Drug: OKT3 5
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OKT3 5 mg just before transplant followed by 4 doses of 5 mg/d.; CyA and prednisone were administered using the same schedule as group A
Trial: 6819969
Drug: Cyclosporin A
RxNorm normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporin A (CsA) with low-dose prednisone
Trial: 31526670
Drug: VMATAuto (automatically
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VMATAuto (automatically generated volumetric modulated arc therapy plans)
Trial: 19898645
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 0.03 mmol BQ123 (selective endothelin A-receptor blocker)
Trial: 17763271
Drug: Continuous intravenous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous intravenous infusion of (1/2) normal saline (NS) at a rate of 1000 mL/h for two hours
Trial: 17763271
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of (1/2) NS at 10 mL/h for two hours
Trial: 11943970
Drug: Home-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Home-based intervention with weekly visits until 6 months postpartum and biweekly visits from 6 to 18 months
Trial: 11943970
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with brief monthly tracking visits
Trial: 9743270
Drug: Modafinil (exact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modafinil (exact dosage and duration not specified)
Trial: 7707852
Drug: Sequential portal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential portal and arterial reperfusion
Trial: 608538
Drug: Corynebacterium parvum,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corynebacterium parvum, 5 mg/m2 i.v.
Trial: 30986119
Drug: 0.05% Cyclosporin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05% Cyclosporin A topical nanoemulsion
Trial: 29961848
Drug: Community scheduled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community scheduled malaria screening and treatment (CSST) with artemether-lumefantrine by community health workers (CHWs) plus IPTp-SP
Trial: 29961848
Drug: Increasing number
RxNorm normalized name: Derma Numb
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increasing number of IPTp-SP doses
Trial: 30187739
Drug: Without treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Without treatment (A0)
Trial: 21557241
Drug: Injection laryngoplasty
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection laryngoplasty
Trial: 2650700
Drug: Low doses
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low doses of n-3 fatty acids
Trial: 2650700
Drug: Very high
RxNorm normalized name: Very high density lipoprotein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Very high doses of n-3 fatty acids
Trial: 2650700
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of n-3 fatty acids
Trial: 69143
Drug: Intravenous aminoacids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous aminoacids
Trial: 69143
Drug: Intravenous fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous fat
Trial: 18392675
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone co-treatment (4 mg daily subcutaneous injection from day 21 of preceding cycle until hCG)
Trial: 18392675
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone co-treatment
Trial: 18392675
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (same treatment protocol without growth hormone)
Trial: 9720330
Drug: i.v. fentanyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. fentanyl 0.1 mg followed by bolus injection of cold propofol premixed with lidocaine (final concentration of lidocaine was 0.2%) in a forearm vein without carrier i.v. fluid
Trial: 9720330
Drug: Induction dose
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction dose of propofol via a vein on the dorsum of the hand at a slow injection speed with carrier i.v. fluid
Trial: 2527891
Drug: Continuation treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuation treatment with nortriptyline or phenelzine
Trial: 51958
Drug: Recombinant WRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant WRL 105 vaccine (10^7.0 E.I.D.50 administered as nose drops)
Trial: 51958
Drug: Recombinant WRL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant WRL 105 vaccine
Trial: 25499666
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35-mg capsules under fasting conditions
Trial: 25499666
Drug: SoluMatrix diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SoluMatrix diclofenac 35-mg capsules under fed conditions
Trial: 25499666
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac potassium IR 50-mg tablets under fasting conditions
Trial: 25499666
Drug: diclofenac potassium
RxNorm normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: diclofenac potassium IR 50-mg tablets under fed conditions
Trial: 23781136
Drug: Procalcitonin-guided antibiotic
RxNorm normalized name: Procalcitonin
DrugBank: Procalcitonin (DB14812)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Procalcitonin-guided antibiotic therapy (threshold of 0.25 ng/ml)
Trial: 23781136
Drug: Routine treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatment (standard practice)
Trial: 21543343
Drug: Aspirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (600 mg/d)
Trial: 21543343
Drug: Resistant Starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant Starch (30 g/d)
Trial: 21543343
Drug: Exploratory endpoint
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exploratory endpoint - Resistant Starch (30 g/d)
Trial: 19221977
Drug: 1,000 mg
RxNorm normalized name: bran 1,000 mg ORAL WAFER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,000 mg pinitol
Trial: 11773285
Drug: Inclusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inclusion of anthracyclines in adjuvant chemotherapy regimens
Trial: 11773285
Drug: Adjuvant dose-intensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant dose-intensive chemotherapy regimens in high-risk breast cancer
Trial: 9731961
Drug: Clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Clobetasol propionate 0.05% ointment bd for 2 weeks followed by calcipotriol 50 microg/g bd for 4 weeks
Trial: 9731961
Drug: Calcipotriol 50
RxNorm normalized name: Calcipotriol 50 microgram/g cutaneous cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcipotriol 50 microg/g bd for 6 weeks
Trial: 30342299
Drug: First-line AAD
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-line AAD therapy
Trial: 24969718
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (Conventional treatment and care)
Trial: 22643350
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg
Trial: 22643350
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Trial: 22643350
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (ETV + TDF)
Trial: 22643350
Drug: Entecavir (ETV)
RxNorm normalized name: Entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Entecavir (ETV) 0.5 mg and Tenofovir disoproxil fumarate (TDF) 300 mg
Trial: 20814005
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the early group (3 to 9 months post-stroke)
Trial: 20814005
Drug: Constraint-Induced Movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-Induced Movement Therapy (CIMT) delivered for 2 weeks to the delayed group (15 to 21 months post-stroke)
Trial: 18514770
Drug: Urine tumor-associated
RxNorm normalized name: Urin DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urine tumor-associated trypsin inhibitor (TATI)
Trial: 12560298
Drug: remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 3 microg x kg(‐1) followed by propofol 2 mg x kg(‐1) (Group I)
Trial: 12560298
Drug: thiopentone 6
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: thiopentone 6 mg x kg(‐1) (Group II)
Trial: 12560298
Drug: etomidate 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: etomidate 0.3 mg x kg(‐1) (Group III)
Trial: 10868866
Drug: intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive insulin therapy + placebo (C) (n = 12)
Trial: 10868866
Drug: intensive insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intensive insulin therapy + nicotinamide, 700 mg three times a day (NIC) (n = 11)
Trial: 10868866
Drug: 72‐h intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 72‐h intravenous insulin followed by intensive insulin therapy + nicotinamide, 700 mg three times a day (NIV) (n = 11)
Trial: 9413735
Drug: Sodium citrate
RxNorm normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium citrate (0.3 g (kg body mass)‐1) 3 h before exercise
Trial: 8105519
Drug: Inhaled terbutaline
RxNorm normalized name: terbutaline Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled terbutaline and salbutamol
Trial: 3517081
Drug: Caffeine and
RxNorm normalized name: caffeine and sodium benzoate
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine and Diazepam combination
Trial: 30570529
Drug: alanine aminotransferase
RxNorm normalized name: Alanine aminotransferase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alanine aminotransferase ≥36 IU/L
Trial: 22585774
Drug: Oral dimenhydrinate
RxNorm normalized name: Dimenhydrinate
DrugBank: Dimenhydrinate (DB00985)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral dimenhydrinate (1 mg/kg; maximum: 50 mg) every 6 hours for 4 doses
Trial: 22585774
Drug: Placebo for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 4 doses
Trial: 17570789
Drug: Lymphatic sparing
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lymphatic sparing (LS) technique with patent blue V dye (2 mL injected under the tunica dartos)
Trial: 12376274
Drug: Intravenous dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous dexamethasone injections at 10 mg
Trial: 7437265
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dapsone (DDS) + 25 mg pyrimethamine (PYR)
Trial: 7437265
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg dapsone (DDS)
Trial: 30267864
Drug: Infliximab monotherapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab monotherapy (5 mg/kg)
Trial: 30267864
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with infliximab and azathioprine (2.5 mg/kg/day)
Trial: 30267864
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with infliximab and azathioprine
Trial: 15459609
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen treatment combined with streptokinase (HBO+)
Trial: 2964548
Drug: NA infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NA infusion
Trial: 31526307
Drug: Dark chocolate
RxNorm normalized name: Ensure Original Dark Chocolate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dark chocolate (1 mg/g of body weight)
Trial: 29173128
Drug: Group cognitive
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group cognitive behavioral therapy (CBT) plus an individually tailored intervention module focused on cognitive conflicts (CCs)
Trial: 19499865
Drug: Coopdech blocker
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Coopdech blocker
Trial: 7530697
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of L-697,639 (25 mg to 500 mg)
Trial: 7530697
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of L-697,639 (up to 100 mg every 12 h for ten days)
Trial: 7530697
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of L-697,639 (200 mg and 500 mg)
Trial: 7530697
Drug: Single doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single doses of L-697,639 (25 mg and 500 mg)
Trial: 7530697
Drug: Multiple doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of L-697,639
Trial: 7530697
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg dose of L-697,639
Trial: 14980912
Drug: Late ambulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late ambulation (Group L)
Trial: 3278234
Drug: Tetracycline ointment
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetracycline ointment
Trial: 23756271
Drug: 50 µg
RxNorm normalized name: penicillin G 50 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg oral misoprostol (two 25 µg tablets)
Trial: 23756271
Drug: 25 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 µg intravaginal misoprostol (one 25 µg tablet)
Trial: 12701817
Drug: Creatine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine supplementation (30 g per day for 14 days)
Trial: 2132029
Drug: High nitrogen
RxNorm normalized name: Isosource High Nitrogen Liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High nitrogen infusion (0.3 g/body weight kg/day)
Trial: 2132029
Drug: Low nitrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low nitrogen infusion (0.1 g/body weight kg/day)
Trial: 24907873
Drug: levobupivacaine 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 6.75 mg + 0.3 mL 2% lidocaine (Group L)
Trial: 24907873
Drug: levobupivacaine 6.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levobupivacaine 6.75 mg + saline (Group C)
Trial: 20308916
Drug: Sodium nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium nitroprusside (SNP) infusion during cardiopulmonary bypass (CPB)
Trial: 20308916
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (control) during cardiopulmonary bypass (CPB)
Trial: 25196873
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF), specific dosage and duration not mentioned
Trial: 25196873
Drug: Corticosteroid treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment, specific dosage and duration not mentioned
Trial: 15692468
Drug: Pimecrolimus cream
RxNorm normalized name: Pimecrolimus
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimecrolimus cream 1% applied twice daily for 2 years
Trial: 7758229
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 12 months
Trial: 7758229
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) replacement therapy (0.04 +/- 0.01 IU/kg daily) for 18 months